Public disclosures

BROADWOOD CAPITAL INC

Company insiders · 10% owner · Lineage Cell Therapeutics, Inc.

Advertisement
FollowLatest SEC filingSEC filer historyProfile details as reported on 2026-11-19.Following & alerts
Reported transaction lines
4
Buy lines
4
Sell lines
0

Filing activity by month

Original filing lines in up to 12 months with activity.

  • 2026-114

Frequently disclosed stocks

Disclosure history

More filters
Clear filters
Reporting investorSecurityActivityTransaction / periodFiledReported amountSource
Joint filing · 3 reporting owners

Lineage Cell Therapeutics, Inc.

LCTX

Lineage Cell Therapeutics, Inc.

Buy
Filing details

SEC transaction code P

Common Shares · Indirect ownership · See Footnote · Reported balance after transaction: 50560992 · SEC code covers open-market or private transactions · The reported securities are directly owned by Broadwood Partners, L.P. ("Broadwood Partners") and may be deemed beneficially owned by Broadwood Capital, Inc. as General Partner of Broadwood Partners and Neal C. Bradsher as President of Broadwood Capital, Inc. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

2026-11-172026-11-19

≈ $0.00

0 shares/units

SEC 4
Joint filing · 3 reporting owners

Lineage Cell Therapeutics, Inc.

LCTX

Lineage Cell Therapeutics, Inc.

Buy
Filing details

SEC transaction code P

Common Shares · Direct ownership · Reported balance after transaction: 50560992 · SEC code covers open-market or private transactions · The reported securities are directly owned by Broadwood Partners, L.P. ("Broadwood Partners") and may be deemed beneficially owned by Broadwood Capital, Inc. as General Partner of Broadwood Partners and Neal C. Bradsher as President of Broadwood Capital, Inc. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

2026-11-172026-11-19

≈ $770,700.00

1,000,000 shares/units

SEC 4
Joint filing · 3 reporting owners

Insight Molecular Diagnostics Inc.

IMDX

Insight Molecular Diagnostics Inc.

Buy
Filing details

SEC transaction code P

Common Stock, no par value · Indirect ownership · Footnote · Reported balance after transaction: 16113455 · SEC code covers open-market or private transactions · The reported securities are directly owned by Broadwood Partners, L.P. ("Broadwood Partners") and may be deemed to be beneficially owned by each of: (i) Broadwood Capital, Inc. ("Broadwood Capital"), as General Partner of Broadwood Partners; and (ii) Neal C. Bradsher, as President of Broadwood Capital. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

2026-11-172026-11-19

≈ $0.00

0 shares/units

SEC 4
Joint filing · 3 reporting owners

Insight Molecular Diagnostics Inc.

IMDX

Insight Molecular Diagnostics Inc.

Buy
Filing details

SEC transaction code P

Common Stock, no par value · Direct ownership · Reported balance after transaction: 16113455 · SEC code covers open-market or private transactions · On November 17, 2026, Broadwood Partners purchased 3,428,571 shares of Common Stock, no par value (the "Common Shares"), of Insight Molecular Diagnostics Inc. (the "Issuer") from the Issuer in an underwritten public offering for a total purchase price of $5,999,999.25, or $1.75 per Common Share. · The reported securities are directly owned by Broadwood Partners, L.P. ("Broadwood Partners") and may be deemed to be beneficially owned by each of: (i) Broadwood Capital, Inc. ("Broadwood Capital"), as General Partner of Broadwood Partners; and (ii) Neal C. Bradsher, as President of Broadwood Capital. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

2026-11-172026-11-19

≈ $5,999,999.25

3,428,571 shares/units

SEC 4

Counts describe original filing lines in BriefStock’s coverage. Later amendments can correct or supplement them. Check the original filing for ownership and transaction details.

Advertisement